RU2004132871A - Новые пептиды и их применение в терапии - Google Patents
Новые пептиды и их применение в терапии Download PDFInfo
- Publication number
- RU2004132871A RU2004132871A RU2004132871/13A RU2004132871A RU2004132871A RU 2004132871 A RU2004132871 A RU 2004132871A RU 2004132871/13 A RU2004132871/13 A RU 2004132871/13A RU 2004132871 A RU2004132871 A RU 2004132871A RU 2004132871 A RU2004132871 A RU 2004132871A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- peptide
- amino acids
- human
- cytokine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 28
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 6
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract 14
- 108090000695 Cytokines Proteins 0.000 claims abstract 12
- 102000004127 Cytokines Human genes 0.000 claims abstract 11
- 230000002163 immunogen Effects 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims abstract 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims abstract 3
- 102000001327 Chemokine CCL5 Human genes 0.000 claims abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract 2
- 238000007792 addition Methods 0.000 claims abstract 2
- 238000012217 deletion Methods 0.000 claims abstract 2
- 230000037430 deletion Effects 0.000 claims abstract 2
- 230000004048 modification Effects 0.000 claims abstract 2
- 238000012986 modification Methods 0.000 claims abstract 2
- 238000007363 ring formation reaction Methods 0.000 claims abstract 2
- 238000006467 substitution reaction Methods 0.000 claims abstract 2
- 235000001014 amino acid Nutrition 0.000 claims 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 claims 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims 2
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims 2
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims 2
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- -1 IL1β Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 101150030763 Vegfa gene Proteins 0.000 claims 2
- 229940044627 gamma-interferon Drugs 0.000 claims 2
- 102000052620 human IL10 Human genes 0.000 claims 2
- 102000056003 human IL15 Human genes 0.000 claims 2
- 102000043959 human IL18 Human genes 0.000 claims 2
- 102000055229 human IL4 Human genes 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 102000019207 human interleukin-13 Human genes 0.000 claims 2
- 229940116886 human interleukin-6 Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940043274 prophylactic drug Drugs 0.000 claims 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 101710091439 Major capsid protein 1 Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 229940040731 human interleukin-12 Drugs 0.000 claims 1
- 229940124829 interleukin-23 Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000002456 anti-arthritic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000007306 functionalization reaction Methods 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Пептид размером от 5 до 40 аминокислот, происходящий от цитокина, отличающийся тем, что по меньшей мере в одной из его аминокислот по меньшей мере один атом находится на расстоянии d менее 5 ангстрем от атома рецептора, соответствующего указанному цитокину, причем расстояние d оценивают на основании структурных данных, за исключением пептидов, расположенных между 2-м и 3-м цистеином h RANTES, MIP1α и MIP1β; и пептидов, расположенных между аминокислотами 123 и 140 IFNα.
2. Пептид по п.1, отличающийся тем, что в двух из его последовательных аминокислот по меньшей мере один атом находится на расстоянии d менее 5 ангстрем от атома рецептора, соответствующего указанному цитокину.
3. Пептид по п.1, отличающийся тем, что его выбирают из фрагментов следующих цитокинов: TGFβ, IL1β, vEGF, TNFα, IFN α и γ, IL 4, 5, 6, 10, 12, 13, 15, 18, 23, IP10, MIP 1α и 1β, MCP1 и Rantes.
4. Пептид по п.3, отличающийся тем, что его выбирают из фрагментов следующих цитокинов: TGFβ, IL1β, vEGF, TNFα, IFN γ, IL 4, 5, 6, 10, 12, 13, 15, 18, 23.
5. Пептид по п.1, отличающийся тем, что d составляет менее 4 ангстрем.
6. Пептид по п.1, отличающийся тем, что 3 или 4 последовательные аминокислоты пептида цитокина отвечают указанному критерию расстояния.
7. Пептид по одному из пп.1-6, отличающийся тем, что он содержит менее 30 аминокислот.
8. Пептид по п.1, выбранный из или происходящий от пептидов, названия которых приведены ниже
или фрагмент указанных пептидов.
9. Производное пептида, определенного в одном из пп.1-8, полученное делецией, заменой, добавлением, циклизацией, стереохимической модификацией (использование аминокислот серии D) или добавлением функциональных групп (например, алкилированием) одной или более аминокислот указанного пептида.
10. Иммуногенное соединение, отличающееся тем, что оно содержит пептид или производное пептида, определенного в одном из пп.1-9, при условии, что оно не содержит других эпитопов указанного цитокина, и тем, что оно способно генерировать в организме пациента антитела, распознающие нативный цитокин.
11. Пептид или производное пептида, или иммуногенное соединение по одному из пп.1-10, или находящийся (находящееся) между аминокислотами 123 и 140 IFNα, для применения в способе терапевтического лечения организма человека или животного.
12. Применение пептида или производного пептида, или иммуногенного соединения по одному из пп.1-10 или находящегося между аминокислотами 123 и 140 IFNα, для получения лечебного или профилактического лекарственного средства, предназначенного для лечения или профилактики нарушений, связанных с избытком или с присутствием цитокинов.
13. Применение пептида или производного пептида, или иммуногенного соединения по одному из пп.1-10 или находящегося между аминокислотами 123 и 140 IFNα, для получения лечебного или профилактического лекарственного средства, предназначенного для лечения аутоиммунных заболеваний.
14. Фармацевтическая композиция, содержащая в качестве действующего начала по меньшей мере один пептид или производное пептида, или иммуногенное соединение по одному из пп.1-10 или находящийся (находящееся) между аминокислотами 123 и 140 IFNα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204464 | 2002-04-10 | ||
FR0204464A FR2838444B1 (fr) | 2002-04-10 | 2002-04-10 | Nouveaux peptides et leur application en therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004132871A true RU2004132871A (ru) | 2005-09-20 |
RU2326125C2 RU2326125C2 (ru) | 2008-06-10 |
Family
ID=28459716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004132871/13A RU2326125C2 (ru) | 2002-04-10 | 2003-04-09 | Новые пептиды и их применение в терапии |
Country Status (20)
Country | Link |
---|---|
US (6) | US7393523B2 (ru) |
EP (3) | EP2314312A3 (ru) |
JP (1) | JP2005530723A (ru) |
KR (1) | KR101101004B1 (ru) |
CN (1) | CN1649898A (ru) |
AT (1) | ATE526985T1 (ru) |
AU (1) | AU2003260031B2 (ru) |
CA (1) | CA2480996C (ru) |
DK (1) | DK2314311T3 (ru) |
ES (2) | ES2550030T3 (ru) |
FR (1) | FR2838444B1 (ru) |
IL (1) | IL164429A0 (ru) |
MA (1) | MA27191A1 (ru) |
MX (1) | MXPA04009841A (ru) |
NZ (1) | NZ536351A (ru) |
RU (1) | RU2326125C2 (ru) |
SI (1) | SI2314311T1 (ru) |
TN (1) | TNSN04200A1 (ru) |
WO (1) | WO2003084979A2 (ru) |
ZA (1) | ZA200408451B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
FR2859725B1 (fr) * | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
CN1960744A (zh) | 2004-02-27 | 2007-05-09 | 瓦克斯咨询公司 | 肽IL1β和TNFα以及应用其治疗的方法 |
KR20080047564A (ko) | 2005-09-28 | 2008-05-29 | 사이토스 바이오테크놀로지 아게 | 인터루킨-1 컨쥬게이트 및 그의 용도 |
JP5750373B2 (ja) * | 2008-11-17 | 2015-07-22 | コーベンハブンス ウニベルシテト | 慢性炎症性応答の調節および自己免疫疾患の処置のためのil−4由来ペプチド |
US9301997B2 (en) | 2009-09-21 | 2016-04-05 | Peptinov Sas | Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides |
WO2011143280A2 (en) | 2010-05-11 | 2011-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling |
EP3663758A1 (en) * | 2012-03-18 | 2020-06-10 | Shiseido Company, Ltd. | Apparatus, system and method for analyzing disease sample |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
CA2986494A1 (en) | 2015-06-03 | 2016-12-08 | Affiris Ag | Il-23-p19 vaccines |
KR102210543B1 (ko) * | 2017-10-13 | 2021-02-01 | 주식회사 나이벡 | 고효율 줄기세포 선별을 위한 grp78 유래 펩타이드 |
WO2020229362A1 (en) * | 2019-05-10 | 2020-11-19 | Tienush Rassaf | Bnip3 peptides for treatment of reperfusion injury |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US5013824A (en) * | 1985-11-19 | 1991-05-07 | Schering Corporation | Human interleukin-4 peptides and conjugates thereof |
DE3841761A1 (de) * | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
CA2071908C (en) * | 1989-12-20 | 2002-04-30 | Lata Ramanathan | Antibody antagonists of human interleukin-4 |
EP0521918A4 (en) * | 1990-03-19 | 1993-05-05 | Peptide Technology Ltd | Anti-tumour peptides |
FR2677654B1 (fr) | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
US6117974A (en) * | 1991-10-02 | 2000-09-12 | Peptor Limited | Libraries of backbone-cyclized peptidomimetics |
US5494662A (en) * | 1992-04-27 | 1996-02-27 | Ono Pharmaceutical Co., Ltd. | Stimulator for bone formation |
WO1994001457A1 (en) * | 1992-07-07 | 1994-01-20 | Fish Eleanor N | Interferon receptor binding peptides |
US5770191A (en) * | 1995-05-24 | 1998-06-23 | University Of Florida | Active C-terminal peptides of interferon--gamma and their use |
US5994292A (en) * | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
CA2279995A1 (en) * | 1997-02-07 | 1998-08-13 | Thomas Jefferson University | Peptide mimetics of the cytokine receptor gamma chain |
IT1291353B1 (it) * | 1997-05-12 | 1999-01-07 | San Raffaele Centro Fond | Peptidi con attivita' antivirale |
WO1999050416A1 (en) * | 1997-09-30 | 1999-10-07 | Pharmacia & Upjohn Company | Tnf-related death ligand |
NZ513507A (en) * | 1999-02-08 | 2003-08-29 | Medvet Science Pty Ltd | Cytokine-binding domain |
WO2000053219A2 (en) * | 1999-03-11 | 2000-09-14 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
US7129072B1 (en) * | 1999-08-30 | 2006-10-31 | New York University | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor |
US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
WO2002044197A2 (en) * | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
US20030166589A1 (en) * | 2001-06-05 | 2003-09-04 | Nathan Karin | Method and pharmaceutical composition for the treatment of multiple sclerosis |
-
2002
- 2002-04-10 FR FR0204464A patent/FR2838444B1/fr not_active Expired - Lifetime
-
2003
- 2003-04-09 EP EP10183961A patent/EP2314312A3/fr not_active Withdrawn
- 2003-04-09 ES ES10183953.8T patent/ES2550030T3/es not_active Expired - Lifetime
- 2003-04-09 KR KR1020047016042A patent/KR101101004B1/ko active IP Right Grant
- 2003-04-09 WO PCT/FR2003/001120 patent/WO2003084979A2/fr active Application Filing
- 2003-04-09 US US10/510,116 patent/US7393523B2/en not_active Expired - Fee Related
- 2003-04-09 DK DK10183953.8T patent/DK2314311T3/en active
- 2003-04-09 AT AT03740584T patent/ATE526985T1/de not_active IP Right Cessation
- 2003-04-09 AU AU2003260031A patent/AU2003260031B2/en not_active Ceased
- 2003-04-09 EP EP03740584A patent/EP1492814B1/fr not_active Expired - Lifetime
- 2003-04-09 MX MXPA04009841A patent/MXPA04009841A/es not_active Application Discontinuation
- 2003-04-09 EP EP10183953.8A patent/EP2314311B1/fr not_active Expired - Lifetime
- 2003-04-09 ES ES03740584T patent/ES2375053T3/es not_active Expired - Lifetime
- 2003-04-09 RU RU2004132871/13A patent/RU2326125C2/ru not_active IP Right Cessation
- 2003-04-09 JP JP2003582175A patent/JP2005530723A/ja active Pending
- 2003-04-09 CA CA2480996A patent/CA2480996C/fr not_active Expired - Fee Related
- 2003-04-09 NZ NZ536351A patent/NZ536351A/en not_active IP Right Cessation
- 2003-04-09 CN CNA038100606A patent/CN1649898A/zh active Pending
- 2003-04-09 SI SI200332450T patent/SI2314311T1/sl unknown
-
2004
- 2004-10-01 MA MA27884A patent/MA27191A1/fr unknown
- 2004-10-05 IL IL16442904A patent/IL164429A0/xx unknown
- 2004-10-08 TN TNP2004000200A patent/TNSN04200A1/fr unknown
- 2004-10-19 ZA ZA2004/08451A patent/ZA200408451B/en unknown
-
2008
- 2008-06-06 US US12/134,743 patent/US7641895B2/en not_active Expired - Lifetime
-
2009
- 2009-12-01 US US12/628,826 patent/US7892529B2/en not_active Expired - Fee Related
-
2011
- 2011-01-11 US US13/004,588 patent/US8147819B2/en not_active Expired - Fee Related
-
2012
- 2012-01-31 US US13/362,234 patent/US8277792B2/en not_active Expired - Fee Related
- 2012-08-24 US US13/593,823 patent/US8529881B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004132871A (ru) | Новые пептиды и их применение в терапии | |
Westwick et al. | Novel neutrophil-stimulating peptides | |
Goldberg et al. | Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27 | |
ATE258444T1 (de) | Therapeutische chemokine rezeptor antagonisten | |
US6656462B2 (en) | Interleukin-1 muteins useful as vaccine adjuvants | |
CN112135623B (zh) | 与疾病的治疗有关的组合物和方法 | |
Sauder | Interleukin 1 | |
US20080305108A1 (en) | Peptides of Il1 Beta and Tnf Alpha and Method Treatment | |
JP2005530723A5 (ru) | ||
US8007776B2 (en) | Vaccine composition comprising interleukin-15 (IL-15) | |
US20220259300A1 (en) | Vaccine composition comprising a mutant of human interleukin-15 | |
JP2023508777A (ja) | インターロイキン-6に対して指向される免疫応答を誘導するための免疫原性複合体 | |
KR20060010730A (ko) | 염증 상태를 치료하고 예방하기 위한 방법과 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190410 |